LLYC

Eli Lilly and Company · VIE:LLYC

1,265.60 EUR−9.60 −0.75%

Eli Lilly and Company (VIE:LLYC) last traded at 1,265.60 EUR, down 0.75% on the day. Over the past year the stock is up 74.04%. Its 52-week range is 730.00 to 1,277.40. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open1,265.60

Day range1,265.60 – 1,265.60

52-week range730.00 – 1,277.40

Volume0

Average volume (10 days)3

Market cap (USD)1.33 T

P/E47.10

EPS (TTM) (USD)30.44

Dividend yield0.47%

Beta (1 year)−0.0156

Revenue (TTM) (USD)86.46 B

Employees50.00 K

Performance

+9.27%1 week

+23.67%1 month

+29.57%3 months

+50.34%6 months

+37.34%Year to date

+74.04%1 year

Technical rating

Buy

Daily summary of 11 oscillators and 15 moving averages. See every indicator

Analysts’ target

1,311.77 EUR

The average 1-year price target, +3.65% from the last price. See the forecast

Latest headlines

Notable healthcare headlines for the week: Eli Lilly, Merck, and AstraZeneca in focusSeeking Alpha · 01 Nov 2026
Healthcare sector rallies in October amid rotation away from technology stocksSeeking Alpha · 31 Oct 2026
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech SkepticismBenzinga · 31 Oct 2026
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3Stocktwits · 31 Oct 2026
Eli Lilly Is Maintained at Buy by UBSDow Jones Newswires · 31 Oct 2026
UBS maintains Eli Lilly at Buy, raises price target to $1625 from $1425TradingView · 31 Oct 2026
What Eli Lilly and Company (LLY) Said on Its Q3 Earnings CallMarketBeat · 30 Oct 2026

Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.